Friday, September 12, 2025

CAMBRIDGE, Mass., September 12, 2025--Scholar Rock (NASDAQ: SRRK; the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults w

Friday, September 12, 2025

Scholar Rock (SRRK) has a 50% to 60% chance of getting US approval with a broad label for its apiteg

Thursday, September 11, 2025

Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of the best multibagger stocks to invest in right now. The company’s stock’s performance was largely supported by optimism around its lead drug candidat

Thursday, August 21, 2025

We recently published 10 Big Names With Surprising Gains. Scholar Rock Holding Corp. (NASDAQ:SRRK) is one of Wednesday’s best performers. Scholar Rock saw its share prices jump by 14.26 percent on Wed

Thursday, August 21, 2025

Scholar Rock Holding (SRRK) just captured the spotlight thanks to a major clinical milestone. The company’s pivotal Phase 3 SAPPHIRE trial results for its lead candidate, apitegromab, were published i

Thursday, August 14, 2025

CAMBRIDGE, Mass., August 14, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscula

Wednesday, August 13, 2025

With a market cap of $3.1 billion, Scholar Rock Holding Corporation appears fairly valued for now. Click here to read an analysis of SRRK stock now.

Tuesday, August 12, 2025

Scholar Rock Holding Corporation (NASDAQ:SRRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Scholar Rock Holding Corporation (NASDAQ:SRRK) reported positive topline results from its

Wednesday, August 6, 2025

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ETCompany ParticipantsAkshay K.

Wednesday, August 6, 2025

The market was hoping the company could better contain its losses.

Wednesday, August 6, 2025

CAMBRIDGE, Mass., August 06, 2025--August 6, 2025-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal m

Monday, July 21, 2025

CAMBRIDGE, Mass., July 21, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SM

Friday, July 11, 2025

The United States market has been flat over the last week but is up 13% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high-growth tech stocks can

Thursday, July 10, 2025

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will solidify its market dominance for the next 5-7 years. Read more.

Monday, June 30, 2025

Scholar Rock Holding Corporation dropped from Russell 3000E Value Index...

Monday, June 30, 2025

Scholar Rock Holding Corporation dropped from Russell 3000E Index...

Monday, June 30, 2025

Scholar Rock Holding Corporation dropped from Russell Microcap Growth Index...

Monday, June 30, 2025

Scholar Rock Holding Corporation dropped from Russell 3000E Growth Index...

Monday, June 30, 2025

Scholar Rock Holding Corporation dropped from Russell Microcap Index...

Sunday, June 29, 2025

Scholar Rock Holding Corporation dropped from Russell Microcap Value Index...

Monday, June 23, 2025

CAMBRIDGE, Mass., June 23, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SM

Monday, June 23, 2025

Friday, June 20, 2025

(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, anal

Thursday, June 19, 2025

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation (NASDAQ:SRRK) is one of the best-performing stocks on Thursday. Scholar Ro

Wednesday, June 18, 2025

Scholar Rock's latest trial returned very positive results. Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Com

Wednesday, June 18, 2025

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a weight-loss drug trial.

Wednesday, June 18, 2025

US equity futures were little changed before Wednesday's opening bell as traders looked ahead to the

Wednesday, June 18, 2025

Presentation Operator MessageOperator Good morning, and welcome to Scholar Rock's presentation of top line data from the Phase II EMBRAZE proof-of-concept trial. [Operator Instructions] This call

Wednesday, June 18, 2025

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad

Wednesday, June 18, 2025

CAMBRIDGE, Mass., June 18, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SM

Wednesday, June 18, 2025

Scholar Rock Holding Corporation and Scholar Rock Inc. , including without limitation, Scholar Rock expectations regarding its growth, strategy, progress and timing of its clinical trials for...

Wednesday, June 18, 2025

Scholar Rock said onWednesday its experimental drug helped overweight patientspreserve more lean mass in a mid-stage trial when used incombination with Eli Lilly's weight-loss treatmentZepbound. ...

Wednesday, June 18, 2025

Scholar Rock said onWednesday its experimental drug helped overweight patientspreserve lean mass in a mid-stage trial when used in combinationwith Eli Lilly's weight-loss treatment Zepbound. ...

Wednesday, June 18, 2025

U.S. stock index futures were mutedon Wednesday ahead of the Federal Reserve's monetary policydecision, as investors traded cautiously amid the ragingIsrael-Iran conflict that entered its sixth...

Wednesday, June 18, 2025

Scholar Rock said onWednesday its experimental drug helped overweight patientspreserve lean mass in a mid-stage trial when used in combinationwith Eli Lilly's weight-loss treatment. ...

Friday, June 13, 2025

Scholar Rock Holding Corp: * SCHOLAR ROCK REPORTS NEW EMPLOYEE INDUCEMENT GRANTS UNDERNASDAQLISTING RULE 5635Source text:Further company coverage: ...

Wednesday, June 11, 2025

Presenter SpeechUnknown Executive Many years of opportunity with our organic pipeline to grow our business. But of course, we'll always be thoughtful I think 1 of the things of Vikas and I, and we...

Friday, June 6, 2025

In the last week, the United States market has been flat, but it is up 11% over the past year with earnings expected to grow by 14% per annum over the next few years. In this context, identifying high

Thursday, June 5, 2025

CAMBRIDGE, Mass., June 05, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SM

Monday, June 2, 2025

CAMBRIDGE, Mass., June 02, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SM

Monday, June 2, 2025

Deep Insights Advancing Impactful Medicines Company Overview | June 2025 ...

Monday, June 2, 2025

Regeneron said on Monday itsexperimental drug helped patients preserve up to 51% of leanmass and lose more fat when used in combination with NovoNordisk's popular obesity drug Wegovy in a...

Wednesday, May 28, 2025

CAMBRIDGE, Mass., May 28, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA

Thursday, May 15, 2025

Scholar Rock Holding Corp (SRRK) reports significant advancements in SMA treatment and prepares for a potential US commercial launch amid financial stability and strategic global expansion.

Thursday, May 15, 2025

Q1 2025 Scholar Rock Holding Corp Earnings Call

Wednesday, May 14, 2025

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q1 2025 Earnings Conference Call May 14, 2025 8:15 AM ETCompany ParticipantsRushmie Nofsinger - VP, Corporate...

Wednesday, May 14, 2025

CAMBRIDGE, Mass., May 14, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA

Wednesday, May 14, 2025

Scholar Rock Holding Corp: * SCHOLAR ROCK Q1 INCOME FROM OPERATIONS USD -77.09 MILLION * SCHOLAR ROCK Q1 OPERATING EXPENSES USD 77.09 MILLION * SCHOLAR ROCK...

Wednesday, May 14, 2025

Scholar Rock Holding Corporation reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 74.72 million compared to USD 56.85.

Wednesday, May 7, 2025

CAMBRIDGE, Mass., May 07, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, an

Wednesday, May 7, 2025

Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by, and welcome to Scholar Rock's First Quarter Financial Results and Business Update Call. [Operator

Monday, May 5, 2025

The United States market has shown a positive trend, with a 2.8% increase over the last week and a 9.3% rise over the past year, while earnings are projected to grow by 14% annually in the coming year

Monday, April 28, 2025

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. Scholar Rock's C-suite now looks radical

Monday, April 28, 2025

CAMBRIDGE, Mass., April 28, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders,

Wednesday, April 23, 2025

Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the company made the rounds. Scholar Rock targets relatively uncommon disorders

Monday, April 21, 2025

Scholar Rock Holding Corp (SRRK) reports promising clinical results and strategic preparations for the launch of apitegromab, while navigating regulatory and competitive landscapes.

Saturday, April 19, 2025

Thursday, April 17, 2025

Thursday, April 3, 2025

In the last week, the United States market has been flat, but over the past 12 months, it has risen by 8.4%, with earnings expected to grow by 14% per annum in the coming years. In this environment, i

Sunday, March 30, 2025

The equity portion of the Abrdn Life Sciences Investors Fund fell (gross) but outperformed its benchmark for Q4 2024. Click here to read the full commentary.

Sunday, March 30, 2025

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.

Tuesday, March 25, 2025

CAMBRIDGE, Mass., March 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders,

Tuesday, March 25, 2025

By Denny Jacob Scholar Rock's biologics license application for apitegromab was accepted by the Food and Drug Administration. The late-stage biopharmaceutical company said the regulator will...

Monday, March 17, 2025

Scholar Rock’s stock is due to drop by 7.49% following the news, according to pre-market estimates.

Sunday, March 16, 2025

CAMBRIDGE, Mass., March 16, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders,

Friday, March 14, 2025

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.

Thursday, March 6, 2025

Scholar Rock Holding Corporation ( NASDAQ:SRRK ) is possibly approaching a major achievement in its business, so we...

Monday, March 3, 2025

Dr. Se-Jin Lee first discovered myostatin in 1997, a protein that is part of a system of checks and balances that limits human muscle growth. That discovery launched an extensive effort in the...

Friday, February 28, 2025

Q4 2024 Scholar Rock Holding Corp Earnings Call

Thursday, February 27, 2025

The following slide deck was published by Scholar Rock Holding Corporation in conjunction with their 2024 Q4 earnings call.

Thursday, February 27, 2025

Scholar Rock Holding Corporation. (NASDAQ:SRRK) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ETCompany ParticipantsJay Backstrom - President...

Thursday, February 27, 2025

CAMBRIDGE, Mass., February 27, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic d

Tuesday, February 25, 2025

CAMBRIDGE, Mass., February 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic d

Monday, February 24, 2025

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against other oversol

Monday, February 24, 2025

CAMBRIDGE - Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy , cardiometabolic disorders, and other serious diseases where..

Friday, February 21, 2025

CAMBRIDGE, Mass., February 21, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic d

Wednesday, February 19, 2025

Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can increase the...

Monday, February 10, 2025

CAMBRIDGE, Mass., February 10, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic d

Saturday, February 8, 2025

This week's earnings releases include consumer companies. A number of IPOs are set to begin trading and Jan. CPI data will be released on Wednesday. See more.

Thursday, January 30, 2025

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

Wednesday, January 29, 2025

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic di

Wednesday, January 29, 2025

CAMBRIDGE, Mass., January 29, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic di

Monday, January 20, 2025

CAMBRIDGE - Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where...

Monday, January 13, 2025

We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) stands against the other s

Wednesday, January 8, 2025

CAMBRIDGE, Mass., January 08, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic di

Thursday, January 2, 2025

CAMBRIDGE, Mass., January 02, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic di

Tuesday, December 24, 2024

Scholar Rock has a promising SMA treatment. Apitegromab's unique approach targets precursor myostatin. See why SRRK stock is hold rated.

Tuesday, December 24, 2024

I analyze Scholar Rock's promising Phase 3 results for SMA drug, but warn of financial challenges and recommend a Hold rating. Read more here.

Wednesday, December 4, 2024

We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. In this article, we are going to take a look at where Scholar Rock Holding Corporat

Monday, November 25, 2024

Scholar Rock (SRRK) shares were surging in afternoon trade after analysts at Wedbush and Truist Securities Monday raised their respective price targets for the biopharmaceutical company's stock.

Monday, November 25, 2024

On Monday, Biohaven Ltd. (NYSE:BHVN) updated the taldefgrobep alfa development programs in Spinal Muscular Atrophy (SMA) and obesity. In the RESILIENT SMA study, taldefgrobep showed clinically meaning

Monday, November 25, 2024

The setback likely removes one competitor to an emerging spinal muscular atrophy medicine from Scholar Rock, but sets the stage for a pair of readouts with implications for weight loss research.

Wednesday, November 13, 2024

Ownership Submission FORM 4 Check this box if no longer...

Wednesday, November 13, 2024

Scholar Rock Holding Corp (SRRK) reports significant progress in its SAPPHIRE study and financial growth, setting the stage for future market expansion.

Tuesday, November 12, 2024

CAMBRIDGE, Mass., November 12, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic d

Tuesday, November 12, 2024

Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2024 Earnings Conference Call November 12, 2024 8:15 AM ETCompany ParticipantsJay Backstrom - President...

Monday, November 4, 2024

CAMBRIDGE, Mass., November 04, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic d

Monday, November 4, 2024

CAMBRIDGE - Scholar Rock , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy , cardiometabolic disorders, and other serious diseases where..

Thursday, October 31, 2024

CAMBRIDGE, Mass., October 31, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic di

Friday, October 25, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 24, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 22, 2024

CAMBRIDGE, Mass., October 22, 2024--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA)

Monday, October 21, 2024

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

Thursday, October 17, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 17, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 16, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 15, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 15, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Saturday, October 12, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Friday, October 11, 2024

Mexican billionaire Carlos Slim switched to a filing usually used by activists for his investment in petroleum refiner PBF Energy. Camac Fund increased its stake in gold miner Gold Reserve.

Friday, October 11, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Friday, October 11, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 10, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, October 10, 2024

Oct. 7, 2024-- Scholar Rock Holding Corporation , a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy , cardiometabolic disorders, and other..

Wednesday, October 9, 2024

Scholar Rock Holding Corp (SRRK) showcases promising developments in its clinical pipeline, with significant progress in SMA and obesity treatments.

Wednesday, October 9, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 9, 2024

Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers.

Wednesday, October 9, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 9, 2024

CAMBRIDGE, Mass., October 09, 2024--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA)

Tuesday, October 8, 2024

Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.

Tuesday, October 8, 2024

Scholar Rock Holding ( (SRRK) ) has provided an announcement. Scholar Rock Holding Corporation has announced promising results from its Phase 3 SAPPHIRE trial, showing significant improvements in moto

Tuesday, October 8, 2024

Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says

Tuesday, October 8, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 8, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 8, 2024

Scholar Rock’s stock price increased by 362% after the company announced its Phase III data.

Tuesday, October 8, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 8, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Scholar Rock stock catapulted by triple digits Monday after its spinal muscular atrophy treatment succeeded in a Phase 3 study.

Monday, October 7, 2024

CAMBRIDGE, Mass., October 07, 2024--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA)

Monday, October 7, 2024

Shares of biotech Scholar Rock more than quadrupled on Monday, adding some $1.9 billion to its market value, after the company said one of its drugs improved motor function in children with a genetic

Monday, October 7, 2024

Scholar Rock aims for a significant market presence with apitegromab in spinal muscular atrophy. See more on SRRK stock and its potential to capture $13B.

Monday, October 7, 2024

Investing.com -- Shares of Scholar Rock Holdings skyrocketed 320% on Monday following the announcement of positive results from its Phase 3 SAPPHIRE clinical trial for apitegromab, a treatment for spi

Monday, October 7, 2024

The biotech says its drug for spinal muscular atrophy, which has no cure, improves motor function in patients.

Monday, October 7, 2024

Update: Scholar Rock's Phase 3 Apitegromab Trial in Spinal Muscular Atrophy Meets Primary Endpoint

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Phase 3 findings could position the biotech’s therapy to become part of a “new standard” for SMA, its CEO said, while boosting research into whether it can preserve muscle in people with obesity.

Monday, October 7, 2024

Positive Topline Results from Pivotal Phase 3 SAPPHIRE Trial of Apitegromab in Spinal Muscular Atrophy October 7, 2024 1 ...

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

CAMBRIDGE, Mass., October 07, 2024--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic di

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy ● ...

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 7, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Friday, September 27, 2024

We recently compiled a list of 10 Worst Falling Stocks To Buy Now. In this article, we will look at where Scholar Rock Holding Corporation (NASDAQ:SRRK) ranks among the 10 worst falling stocks to buy

Friday, September 27, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.